FDA reiterates importance of close patient supervision for ‘Off-Label’ use of antimalarial drugs to mitigate known risks

Alert warns healthcare professionals should closely supervise patients on chloroquine and hydroxychloroquine, especially as potentially life-threatening cardiovascular events have been reported with their use for treatment of COVID-19, for which they are not approved by the FDA.


US Food and Drug Administration